Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO: Impact of common antidepressants on tamoxifen effectiveness

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 18 Jun 2009

Views: 14430

Rating:

Save

Dr. Vincent O. Dezentjé - Leiden University Medical Center, Leiden, The Netherlands

ASCO press conference: Two studies report differing results about whether the antidepressants, fluoxetine and paroxetine, have an adverse impact on the effectiveness of tamoxifen.

Categories:
Breast
Drug development

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA

Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

More from ecancer